CCND1 and irritable bowel syndrome: Treatment with two different doses of IBS and MBS (2 mg/kg and 4 mg/kg) significantly reduced the percentage of CD5+CD19+ cells in the peripheral blood and spleen of BCL1-injected BALB/c mice (Figure 6a,b).